Open access · CC-BY
via OpenAlex
Nuclear Alpha‐Synuclein in Parkinson’s Disease and the Malignant Transformation in Melanoma
María Esther Jiménez-Capdeville, Érika Chi-Ahumada, Francisco García-Ortega, Juan Pablo Castanedo-Cázares, Robert A. Norman, Ildefonso Rodríguez‐Leyva
Neurology Research International · 2025 · ▲ 3 citations
Abstract
Background: Alpha‐synuclein (ASyn), a marker of Parkinson’s disease (PD) and other neurodegenerative processes, plays pivotal roles in neuronal nuclei and synapses. ASyn and its phosphorylated form at Serine 129 (p‐ASyn) are involved in DNA protection and repair, processes altered in aging, neurodegeneration, and cancer. Objective: To analyze the localization of p‐ASyn in skin biopsies of PD patients and melanoma. Methods: Biopsies from 26 PD patients, 20 melanoma patients, and 31 control subjects were probed and analyzed with a p‐ASyn antibody by immunohistochemistry and immunofluorescence. Nuclear positivity was quantified by image analysis. Results: Peripheral nerve endings from healthy subjects show little p‐ASyn immunopositivity but notable axonal presence in PD. Control subjects show immunopositivity to p‐ASyn along all epidermic strata and scarce presence in their cytoplasm. In contrast, its nuclear presence in PD is weaker, with a higher cytoplasmic and intercellular presence. Nuclear p‐ASyn in melanoma varied from similar to control skin in early stage melanoma to a higher rate of empty nuclei in the intermediate stage and total absence of nuclear p‐ASyn in severe cases. Interpretation: These findings support the nuclear localization of p‐ASyn in skin cells and show that its presence decreases PD and almost disappears in the malignant transformation of melanocytes, redistributing to the cytoplasm and intercellular spaces. This confirms the association between PD and melanoma, providing crucial insights into the role of p‐ASyn in both diseases. Trial Registration: ClinicalTrials.gov identifier: NCT01380899 .
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1155/nri/1119424
- Canonical
- link ↗
- Fetched
- 2026-10-27 MST
Cite this
APA
Jiménez-Capdeville, M.E., Chi-Ahumada, �., García-Ortega, F., Castanedo-Cázares, J.P., Norman, R.A., & Rodríguez‐Leyva, I. (2025). Nuclear Alpha‐Synuclein in Parkinson’s Disease and the Malignant Transformation in Melanoma. <em>Neurology Research International</em>. https://doi.org/10.1155/nri/1119424
Vancouver
Jiménez-Capdeville ME, Chi-Ahumada �, García-Ortega F, Castanedo-Cázares JP, Norman RA, Rodríguez‐Leyva I. Nuclear Alpha‐Synuclein in Parkinson’s Disease and the Malignant Transformation in Melanoma. Neurology Research International. 2025. doi:10.1155/nri/1119424.
BibTeX
@article{mara2025Nuclea,
title = {Nuclear Alpha‐Synuclein in Parkinson’s Disease and the Malignant Transformation in Melanoma},
author = {María Esther Jiménez-Capdeville and Érika Chi-Ahumada and Francisco García-Ortega and Juan Pablo Castanedo-Cázares and Robert A. Norman and Ildefonso Rodríguez‐Leyva},
journal = {Neurology Research International},
year = {2025},
doi = {10.1155/nri/1119424},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Acta Neuropathologica 2024
Open access · CC-BY
Distinct tau and alpha-synuclein molecular signatures in Alzheimer’s disease with and without Lewy bodies and Parkinson’s disease with dementia
Movement Disorders Clinical Practice 2017
Open access · OA
The Presence of Alpha‐Synuclein in Skin from Melanoma and Patients with Parkinson's Disease
Neurology 2015
Open access · OA
Colonic mucosal α-synuclein lacks specificity as a biomarker for Parkinson disease
npj Parkinson s Disease 2022
Open access · CC-BY
Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies
Acta Neuropathologica 2026
Open access · CC-BY
Molecular profiling of alpha-synuclein pathology and seeding activity in Parkinson’s disease
Annals of Clinical and Translational Neurology 2014
Open access · CC-BY